NEWS & MEDIA

Osteo-Pharma Receives Notice of Intention to Grant the New Composition of Matter Patent Covering OsteoActivator® Formulations

Feb 7, 2018

Osteo-Pharma BV announced today that it received formal notice that the European Patent Office’s Examining Division issued the formal notification of intention to grant the Osteo-Pharma patent application titled “Compositions and products for use in the treatment of...

Osteo-Pharma announces Scientific Advisory Board

Jun 22, 2016

Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, announced its Scientific Advisory Board (SAB) comprising experts in the field of bone and dental regenerative biology from the U.S. and Europe.

Osteo-Pharma receives up to € 2 Million Innovation Credit from Dutch Government

Jun 16, 2016

Oss, The Netherlands – June 16, 2016 – Osteo-Pharma BV, a Life Sciences company focusing on the development of local treatments to improve the healing of bone fractures and defects, announces today that it has received an innovation credit of up to € 2 million from the Rijksdienst voor Ondernemers (RVO), an agency executing programs for the Dutch Ministry of Economic Affairs, Agriculture and Innovation.

About Osteo-Pharma Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-late stage pre-clinical development with various projects and anticipates to initiate the first human clinical trials in the course of 2017/2018.